AKT1 Genotype

If you use cannabis, one inherited gene variant may quietly shape how your brain reacts to it. This is the most studied example researchers have found of a gene that may change cannabis-related psychosis risk rather than causing psychosis on its own.

This is a research-stage marker, not a routine clinical test, and no psychiatric or genetics guideline currently recommends AKT1 genotyping for any purpose. It will not tell you whether you will develop a disease, but it can flag an inherited susceptibility that standard blood panels never look at.

What This Test Actually Reads

The test reports your AKT1 genotype (your inherited version of the AKT1 gene, which carries instructions for a cell-signaling protein called protein kinase B alpha). This protein sits at the center of a network that tells cells when to grow, survive, and use energy. Because you inherit it and it is present in every cell, your result is fixed for life.

AKT1 does different jobs in different tissues, which is why a single genotype can matter for brain chemistry, metabolism, and cancer biology in ways that do not always point the same direction. That is the key to reading your result honestly: it is a context-specific modifier, not a verdict.

Cannabis and Psychosis Risk

The most studied finding is that AKT1 genotype may change how cannabis affects psychosis risk. The variant does not predict psychosis by itself. It acts as a modifier. The evidence is promising but not settled: some studies support this interaction and others have not reproduced it.

In a study of 767 people, daily cannabis users carrying two copies of the C variant at a spot called rs2494732 (a C/C result) had about seven times the odds of a psychotic disorder compared with daily users carrying two T copies (T/T), though the range around that estimate was wide. Carrying C/C overall was tied to more than double the likelihood of a psychotic disorder versus T/T.

In 442 young cannabis smokers, the same variant predicted a stronger short-term psychotic-like response to smoked cannabis. In people with a psychotic disorder, cannabis use before illness onset interacted with this variant to worsen sustained attention, while verbal memory showed no such interaction. Most of these studies were done in people of European ancestry, so how well they apply to other backgrounds is not clear.

What this means for you: if you carry the higher-risk genotype and use cannabis regularly, that combination may matter more for your mental health than either factor alone. It is a reason to think carefully about cannabis use, not a diagnosis.

Brain Signaling and Cognition

A coding version of AKT1 that changes how much protein cells make has been linked to dopamine-related brain features in humans, including prefrontal thinking skills, brain physiology, and gray-matter volume. This fits AKT1's role in dopamine signaling, the brain chemistry system involved in reward, attention, and psychosis. The effect also depended partly on another gene, COMT, which shapes how the brain clears dopamine.

Type 2 Diabetes and Metabolic Markers

Metabolic links are more mixed than the cannabis findings. In a Chinese case-control study, two variants (rs2494746 and rs2494738) were tied to higher type 2 diabetes risk, with carriers roughly 1.5 to 1.8 times as likely to have diabetes. Other studies in different populations have found no such link, which is why these are treated as population-specific signals rather than fixed rules.

A different variant, rs1130233, was not linked to metabolic syndrome overall in a Middle Eastern cohort study, but certain genotypes were associated with higher levels of a body-wide inflammation marker (hs-CRP, a blood test for inflammation) and higher body weight. These are population-specific signals, not confirmed clinical rules.

Inherited Variants Versus Tumor Mutations in Cancer

Here the distinction matters most. A germline AKT1 genotype test reads the AKT1 gene you inherited, present in every cell. That is different from a tumor test that looks for AKT1 mutations a cancer picks up on its own, such as the E17K mutation used to select certain targeted cancer drugs. Those tumor mutations are found by sequencing a biopsy or tumor DNA in the blood, not by an inherited genotype test.

Among people who already have certain cancers, inherited AKT1 variants have been linked to survival, recurrence, or treatment response in early-stage lung, oral, gastric, esophageal, and pancreatic cancers. In one early-stage lung cancer study, patients carrying two unfavorable AKT1 genotypes had roughly three times the risk of dying during follow-up. In gastric cancer, one genotype was tied to about 30 percent lower recurrence and higher survival.

The direction of risk flips between studies and cancer types, so these are research signals rather than a basis for cancer screening in healthy people.

Why the Same Gene Points Both Ways

This is not a good-genotype, bad-genotype marker. Because AKT1 sits in a signaling network that does different jobs in different tissues, the same variant can raise risk in one setting and lower it in another. In one vasculitis study, some AKT1 variants were even tied to reduced disease risk. An inherited AKT1 result is best read as a modifier that only means something alongside a specific exposure or disease, not a single answer about your future health.

COVID-19 Severity and Other Early Signals

A 2024 study of 508 people linked one AKT1 variant (rs2494746-C) to more severe COVID-19, including intensive care admission and death, and another (rs1130214) to higher inflammatory and clotting markers. This is early, single-disease evidence that has not been widely replicated; the largest genetic studies of severe COVID-19 point to other genes as the strongest drivers, not AKT1.

Where the Evidence Falls Short

Not every association holds up. In depression, two variants were not linked to whether someone had the illness, though one was tied to how well people responded to antidepressants. In bipolar disorder, a larger Swedish replication study of 2,327 people found no meaningful link. In a healthy, non-clinical sample, the cannabis-cognition interaction seen in people with psychosis did not replicate. And a later study pooling about 720 people found no link between AKT1 genotype and cannabis-induced psychotic-like experiences, so even the best-known cannabis interaction is not fully settled.

What a One-Time Result Gives You

Your AKT1 genotype is set at conception and does not change, so this is a one-time test. There is no trend to track and no reason to repeat it unless a lab needs to confirm the reading with a second method. The value comes from folding the result into decisions you make over years, not from testing again.

If your result flags metabolic or inflammatory variants, the useful follow-up is not to recheck the gene but to keep an eye on the downstream numbers it might nudge, such as blood sugar (HbA1c), fasting glucose, and inflammation (hs-CRP), at least once a year.

Making Sense of an Unexpected Result

An AKT1 genotype result rarely stands on its own. If yours flags a cannabis-related psychosis variant and you use cannabis, the most useful next step is an honest conversation about that exposure with a clinician familiar with mental health, rather than any additional lab. If it flags metabolic variants, pair it with a metabolic panel and inflammation markers instead of treating the genotype as the answer. Because the meaning depends heavily on ancestry, exposure, and which exact variant you carry, a genetic counselor or the relevant specialist is the right person to interpret a surprising result.

Why This Result Can Mislead

• Panel coverage: the test only reports the specific spots it is designed to read, so a result that does not flag a risk variant does not rule out other rare changes in the same gene.
• Ancestry matters: much of the AKT1 evidence comes from specific populations, with the cannabis-psychosis work done mostly in European-ancestry groups and several metabolic and cancer findings in East Asian cohorts, so a variant that raises risk in one background can be common and unremarkable in another.
• Inherited versus tumor DNA: this test reads the gene you were born with and does not detect the AKT1 mutations a cancer picks up on its own, such as E17K, which require a tumor or tumor-DNA test.
• Uncertain variants: an occasional finding may be reported with unknown meaning, which is a reason for careful interpretation rather than alarm.